Yu-Xia Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu-Xia Zhao has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Yun Zhang
State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
9 shared publicationsXue Liu
The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China
4 shared publicationsBo Wang
Department of Traditional Chinese Medicine, Qilu Hospital, Shandong University, Jinan, Shandong, China
3 shared publicationsCheng Zhang
The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health , Qilu Hospital, Shandong University , No. 107, Wenhua Xi Road, Jinan, Shandong 250012 , PR China
3 shared publicationsXiuhui Song
The People’s Hospital of Jimo City, Qingdao, Shandong 266200, China
3 shared publicationsYuan-Yuan Sun
3 shared publications
Latest Publications
- Open Access
- 13 January 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1540602
Editorial: TRLs (triglycerides-rich lipoproteins): a new target for atherosclerosis
With the deepening understanding of the important role of triglycerides in blood, new metabolic markers related to triglycerides have been applied in clinical practice. Based on the i research of Liu et al., the ratio of triglycerides to high-density lipoprotein cholesterol (TG/HDL-C) is associated with insulin resistance, high risk of cerebrovascular disease, prognosis of kidney disease, occurrence of coronary heart disease, and prognosis of myocardial infarction patients. In addition, Chen et al. found in their latest study that a higher TG/HDL-C ratio is significantly associated with an increased risk of peripartum cardiomyopathy (PPCM) [3] . The plasma atherosclerotic index AIP, calculated as log10 (TG/HDL-C), has been recognized as a new practical marker for assessing cardiac metabolic risks, such as coronary artery disease (CAD) risk and insulin resistance related diseases.However, the relevance of AIP as a prognostic biomarker for coronary artery disease (CAD) remains controversial. Huang et al. demonstrated through a retrospective cohort study that there is a U-shaped relationship between the incidence of repeat target vessel revascularization (TVR) after drug-eluting stent (DES) implantation in AIP and CAD patients, particularly in females [4] . These studies indicate that TG and its cholesterol rich metabolites play important roles in the development of various diseases and may become powerful new clinical biomarkers.Understanding the metabolic pathways of TG and TRLs and their fundamental pathological mechanisms in AS is crucial. Exogenous TG synthesized in the small intestine and endogenous TG synthesized in the liver are secreted into the bloodstream through CM and VLDL, assembled with apolipoprotein, and then hydrolyzed by lipoprotein lipase (LPL) secreted by adipose tissue storage, muscle tissue, and heart. The residual particles produced during this period are cleared by the liver. TRLs and their residues, which have been retained in the arterial wall for a long time, become proinflammatory after modification, induce monocytes to recruit and differentiate into macrophage phagolipoproteins, and form foam cells. Pro-inflammatory TRL can also induce VSMCs to transform into macrophage like cells, exacerbating pre-existing inflammatory responses by secreting various pro-inflammatory cytokines, thereby promoting atherosclerosis.In addition, other lipoproteins can promote atherosclerosis by regulating the activity of LPL. Elevated ApoCIII levels can inhibit LPL activity and liver uptake of VLDL residues, prolong the retention of TRL residues in plasma, and enhance cholesterol binding. Angiopoietin like protein 3 (ANGPTL3) plays an important role in regulating TRL metabolism by inhibiting LPL activity. This research topic includes two key reviews. Gugliucci focuses on the synthesis and catabolism of postprandial chylomicron residues in vivo, and proposes important clinical significance and detection methods for postprandial plasma lipoprotein evaluation [5] . Xu et al. investigated the role of TRL residues in promoting AS progression and discussed potential targets for blocking and reducing TRLs [6] . Both reviews emphasize the importance of understanding these processes, which may identify potential new drug targets to reduce or even reverse the occurrence of AS, ultimately improving patient prognosis. Quratul et al. described the genetic and clinical characteristics of patients with lipoprotein lipase deficiency through case analysis and systematic literature review. Familial chylomicronemia (FCS) is a rare recessive genetic disorder, with the majority of FCS cases (approximately 95%) associated with specific pathogenic variations in the lipoprotein lipase (LPL) gene. Research has shown that this LPL deficiency will lead to the accumulation of lipoproteins rich in triglycerides, clinically manifested as hypertriglyceridemia (HTG), as well as a higher risk of pancreatitis and cardiovascular disease. This indicates that LPL may have broad potential in reducing plasma TG and TRLs [7] .The drugs currently used in clinical practice to reduce triglycerides include beta blockers and niacin, which activate peroxisome proliferator activated receptor alpha (PPAR alpha), induce LPL expression, and reduce serum TG levels. ii In the research meta-analysis of Chukwurah et al., fenofibrate did not significantly improve the ASCVD outcome in individuals with type 2 diabetes, but subgroup analysis showed that these patients had a much lower risk of suffering from the disease. Omega-3 polyunsaturated fatty acid preparations have been tested in large-scale ASCVD outcome studies, and overall, their benefits in reducing ASCVD risk provide only weak evidence.At present, research on creating compounds for treating hypertriglyceridemia mainly focuses on increasing TRL lipolysis. ApoIII and ANGPTL3 are currently the main targets. The current research trend focuses on interfering with or inhibiting ANGPTL3 through various methods, including ANGPTL3 monoclonal antibodies, antisense oligonucleotides (ASO), and gene editing techniques. In animal and human studies, these substances (apoCIII and ANGPTL3 inhibitors) reduced the levels of apoCII and ANGPTL2 in plasma by approximately 70% and 80%, respectively. Moreover, studies have shown that antisense oligonucleotides targeting apoCIII can significantly reduce triglyceride levels even in FCS patients, making it the first drug currently available for these patients [5] .The current research results indicate that TG and TRLs may become new potential targets for AS detection and treatment besides LDL-C. Further comprehensive understanding of potential pathological biology and related clinical research are crucial for the development of new biomarkers and therapeutic drugs. At present, there is no reliable technology to directly measure serum TRLs and TRLs residues in clinical practice, which poses a challenge in accurately assessing the risk and prognosis...
- 13 January 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1540602
Open AccessEditorial: TRLs (triglycerides-rich lipoproteins): a new target for atherosclerosis
With the deepening understanding of the important role of triglycerides in blood, new metabolic markers related to triglycerides have been applied in clinical practice. Based on the i research of Liu et al., the ratio of triglycerides to high-density lipoprotein cholesterol (TG/HDL-C) is associated with insulin resistance, high risk of cerebrovascular disease, prognosis of kidney disease, occurrence of coronary heart disease, and prognosis of myocardial infarction patients. In addition, Chen et al. found in their latest study that a higher TG/HDL-C ratio is significantly associated with an increased risk of peripartum cardiomyopathy (PPCM) [3] . The plasma atherosclerotic index AIP, calculated as log10 (TG/HDL-C), has been recognized as a new practical marker for assessing cardiac metabolic risks, such as coronary artery disease (CAD) risk and insulin resistance related diseases.However, the relevance of AIP as a prognostic biomarker for coronary artery disease (CAD) remains controversial. Huang et al. demonstrated through a retrospective cohort study that there is a U-shaped relationship between the incidence of repeat target vessel revascularization (TVR) after drug-eluting stent (DES) implantation in AIP and CAD patients, particularly in females [4] . These studies indicate that TG and its cholesterol rich metabolites play important roles in the development of various diseases and may become powerful new clinical biomarkers.Understanding the metabolic pathways of TG and TRLs and their fundamental pathological mechanisms in AS is crucial. Exogenous TG synthesized in the small intestine and endogenous TG synthesized in the liver are secreted into the bloodstream through CM and VLDL, assembled with apolipoprotein, and then hydrolyzed by lipoprotein lipase (LPL) secreted by adipose tissue storage, muscle tissue, and heart. The residual particles produced during this period are cleared by the liver. TRLs and their residues, which have been retained in the arterial wall for a long time, become proinflammatory after modification, induce monocytes to recruit and differentiate into macrophage phagolipoproteins, and form foam cells. Pro-inflammatory TRL can also induce VSMCs to transform into macrophage like cells, exacerbating pre-existing inflammatory responses by secreting various pro-inflammatory cytokines, thereby promoting atherosclerosis.In addition, other lipoproteins can promote atherosclerosis by regulating the activity of LPL. Elevated ApoCIII levels can inhibit LPL activity and liver uptake of VLDL residues, prolong the retention of TRL residues in plasma, and enhance cholesterol binding. Angiopoietin like protein 3 (ANGPTL3) plays an important role in regulating TRL metabolism by inhibiting LPL activity. This research topic includes two key reviews. Gugliucci focuses on the synthesis and catabolism of postprandial chylomicron residues in vivo, and proposes important clinical significance and detection methods for postprandial plasma lipoprotein evaluation [5] . Xu et al. investigated the role of TRL residues in promoting AS progression and discussed potential targets for blocking and reducing TRLs [6] . Both reviews emphasize the importance of understanding these processes, which may identify potential new drug targets to reduce or even reverse the occurrence of AS, ultimately improving patient prognosis. Quratul et al. described the genetic and clinical characteristics of patients with lipoprotein lipase deficiency through case analysis and systematic literature review. Familial chylomicronemia (FCS) is a rare recessive genetic disorder, with the majority of FCS cases (approximately 95%) associated with specific pathogenic variations in the lipoprotein lipase (LPL) gene. Research has shown that this LPL deficiency will lead to the accumulation of lipoproteins rich in triglycerides, clinically manifested as hypertriglyceridemia (HTG), as well as a higher risk of pancreatitis and cardiovascular disease. This indicates that LPL may have broad potential in reducing plasma TG and TRLs [7] .The drugs currently used in clinical practice to reduce triglycerides include beta blockers and niacin, which activate peroxisome proliferator activated receptor alpha (PPAR alpha), induce LPL expression, and reduce serum TG levels. ii In the research meta-analysis of Chukwurah et al., fenofibrate did not significantly improve the ASCVD outcome in individuals with type 2 diabetes, but subgroup analysis showed that these patients had a much lower risk of suffering from the disease. Omega-3 polyunsaturated fatty acid preparations have been tested in large-scale ASCVD outcome studies, and overall, their benefits in reducing ASCVD risk provide only weak evidence.At present, research on creating compounds for treating hypertriglyceridemia mainly focuses on increasing TRL lipolysis. ApoIII and ANGPTL3 are currently the main targets. The current research trend focuses on interfering with or inhibiting ANGPTL3 through various methods, including ANGPTL3 monoclonal antibodies, antisense oligonucleotides (ASO), and gene editing techniques. In animal and human studies, these substances (apoCIII and ANGPTL3 inhibitors) reduced the levels of apoCII and ANGPTL2 in plasma by approximately 70% and 80%, respectively. Moreover, studies have shown that antisense oligonucleotides targeting apoCIII can significantly reduce triglyceride levels even in FCS patients, making it the first drug currently available for these patients [5] .The current research results indicate that TG and TRLs may become new potential targets for AS detection and treatment besides LDL-C. Further comprehensive understanding of potential pathological biology and related clinical research are crucial for the development of new biomarkers and therapeutic drugs. At present, there is no reliable technology to directly measure serum TRLs and TRLs residues in clinical practice, which poses a challenge in accurately assessing the risk and prognosis...
- Open Access
- 15 May 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Editorial: Fibrosis: etiology, pathophysiology, measurements, and therapy
Editorial: Fibrosis: etiology, pathophysiology, measurements, and therapy
- 15 May 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Open AccessEditorial: Fibrosis: etiology, pathophysiology, measurements, and therapy
Editorial: Fibrosis: etiology, pathophysiology, measurements, and therapy
- Open Access
- 15 June 2022
- Published by Impact Journals, LLC in Oncotarget
- Vol. 13 (1) , 810-811
Correction: Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice
[This corrects the article DOI: 10.18632/oncotarget.11225.].
- 15 June 2022
- Published by Impact Journals, LLC in Oncotarget
- Vol. 13 (1) , 810-811
Open AccessCorrection: Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice
[This corrects the article DOI: 10.18632/oncotarget.11225.].
- Open Access
- 16 March 2018
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 52 (5) , 1415-1426
Genome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cells
Bromodomain containing 4 (BRD4), a member of the bromodomain and extra-terminal family, has become a promising drug target for numerous types of cancer. BRD4 has been reported to be deregulated in gliomas; however, the precise molecular pathways regulated by BRD4 remained elusive. In the present study, BRD4 expression was silenced in the glioma cell line U251 and the results demonstrated that BRD4 knockdown attenuated cell proliferation and promoted cell apoptosis. A genome-wide analysis of BRD4-regulated transcripts in U251 cells was performed using microarray to reveal the possible molecular mechanism. A total of 3,529 differentially expressed genes were identified; 1,648 of these genes were upregulated and 1,881 were downregulated. The results of the gene ontology analysis revealed that these genes were mainly involved in membrane organization, mitotic cell cycle, cell division and DNA replication. Pathway analysis revealed that the pathways altered following BRD4 knockdown included multiple cellular processes, such as cell cycle and apoptosis. Candidate genes were identified through global signal transduction network analysis and were validated using reverse transcription-quantitative polymerase chain reaction and western blot analyses. The results demonstrated that BRD4 knockdown decreased the expression of KRAS proto-oncogene GTPase (KRAS). Downregulated KRAS expression in U251 cells restrained cell proliferation and promoted cell apoptosis, suggesting that the effect of BRD4 on glioma cells might occur through the Ras pathway. In conclusion, the present results confirmed the role of BRD4 in glioma and provided information for further exploration of the molecular mechanism of BRD4 in glioma development and progression.
- 16 March 2018
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 52 (5) , 1415-1426
Open AccessGenome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cells
Bromodomain containing 4 (BRD4), a member of the bromodomain and extra-terminal family, has become a promising drug target for numerous types of cancer. BRD4 has been reported to be deregulated in gliomas; however, the precise molecular pathways regulated by BRD4 remained elusive. In the present study, BRD4 expression was silenced in the glioma cell line U251 and the results demonstrated that BRD4 knockdown attenuated cell proliferation and promoted cell apoptosis. A genome-wide analysis of BRD4-regulated transcripts in U251 cells was performed using microarray to reveal the possible molecular mechanism. A total of 3,529 differentially expressed genes were identified; 1,648 of these genes were upregulated and 1,881 were downregulated. The results of the gene ontology analysis revealed that these genes were mainly involved in membrane organization, mitotic cell cycle, cell division and DNA replication. Pathway analysis revealed that the pathways altered following BRD4 knockdown included multiple cellular processes, such as cell cycle and apoptosis. Candidate genes were identified through global signal transduction network analysis and were validated using reverse transcription-quantitative polymerase chain reaction and western blot analyses. The results demonstrated that BRD4 knockdown decreased the expression of KRAS proto-oncogene GTPase (KRAS). Downregulated KRAS expression in U251 cells restrained cell proliferation and promoted cell apoptosis, suggesting that the effect of BRD4 on glioma cells might occur through the Ras pathway. In conclusion, the present results confirmed the role of BRD4 in glioma and provided information for further exploration of the molecular mechanism of BRD4 in glioma development and progression.
- Open Access
- 1 January 2018
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2018 (1) , 9086747
Andrographolide Ameliorates Diabetic Cardiomyopathy in Mice by Blockage of Oxidative Damage and NF‐κB‐Mediated Inflammation
Andrographolide (Andro), a major bioactive component obtained from Andrographis paniculata Nees, has exerted wide antioxidant as well as cytoprotective properties. However, whether Andro treatment could retard the progress of diabetic cardiomyopathy (DCM) remains unknown. In this study, we evaluated the effects of Andro against diabetes‐induced myocardial dysfunction and explored the underlying mechanism in STZ‐induced diabetic mice. As a result, treatment with Andro dose dependently suppressed cardiac inflammation and oxidative stress, accompanied by decreasing cardiac apoptosis, which subsequently ameliorated cardiac fibrosis and cardiac hypertrophy. Further, Andro blocked hyperglycemia‐triggered reactive oxygen species (ROS) generation by suppressing NADPH oxidase (NOX) activation and augmenting nuclear factor erythroid 2‐related factor 2 (Nrf2) expression both in vitro and in vivo. Our results suggest that the cardioprotective effects afforded by Andro treatment involve the modulation of NOX/Nrf2‐mediated oxidative stress and NF‐κB‐mediated inflammation. The present study unravels the therapeutic potential of Andro in the treatment of DCM by attenuating oxidative stress, inflammation, and apoptosis.
- 1 January 2018
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2018 (1) , 9086747
Open AccessAndrographolide Ameliorates Diabetic Cardiomyopathy in Mice by Blockage of Oxidative Damage and NF‐κB‐Mediated Inflammation
Andrographolide (Andro), a major bioactive component obtained from Andrographis paniculata Nees, has exerted wide antioxidant as well as cytoprotective properties. However, whether Andro treatment could retard the progress of diabetic cardiomyopathy (DCM) remains unknown. In this study, we evaluated the effects of Andro against diabetes‐induced myocardial dysfunction and explored the underlying mechanism in STZ‐induced diabetic mice. As a result, treatment with Andro dose dependently suppressed cardiac inflammation and oxidative stress, accompanied by decreasing cardiac apoptosis, which subsequently ameliorated cardiac fibrosis and cardiac hypertrophy. Further, Andro blocked hyperglycemia‐triggered reactive oxygen species (ROS) generation by suppressing NADPH oxidase (NOX) activation and augmenting nuclear factor erythroid 2‐related factor 2 (Nrf2) expression both in vitro and in vivo. Our results suggest that the cardioprotective effects afforded by Andro treatment involve the modulation of NOX/Nrf2‐mediated oxidative stress and NF‐κB‐mediated inflammation. The present study unravels the therapeutic potential of Andro in the treatment of DCM by attenuating oxidative stress, inflammation, and apoptosis.
- Open Access
- 23 October 2017
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (2) , 808-822
Irisin inhibits high glucose‐induced endothelial‐to‐mesenchymal transition and exerts a dose‐dependent bidirectional effect on diabetic cardiomyopathy
Emerging evidence indicates that irisin provides beneficial effects in diabetes. However, whether irisin influences the development of diabetic cardiomyopathy (DCM) remains unclear. Therefore, we investigated the potential role and mechanism of action of irisin in diabetes‐induced myocardial dysfunction in mice. Type 1 diabetes was induced in mice by injecting streptozotocin, and the diabetic mice were administered recombinant r‐irisin (low or high dose: 0.5 or 1.5 μg/g body weight/day, I.P.) or PBS for 16 weeks. Irisin treatment did not alter blood glucose levels in the diabetic mice. However, the results of echocardiographical and histopathological assays indicated that low‐dose irisin treatment alleviated cardiac fibrosis and left ventricular function in the diabetic mice, whereas high‐dose irisin failed to mitigate the ventricular function impairment and increased collagen deposition. The potential mechanism underlying the effect of low‐dose irisin involved irisin‐mediated inhibition of high glucose‐induced endothelial‐to‐mesenchymal transition (EndMT); conversely, high‐dose irisin treatment enhanced high glucose‐induced MMP expression by stimulating MAPK (p38 and ERK) signalling and cardiac fibroblast proliferation and migration. Low‐dose irisin alleviated DCM development by inhibiting high glucose‐induced EndMT. By contrast, high‐dose irisin disrupted normal MMP expression and induced cardiac fibroblast proliferation and migration, which results in excess collagen deposition. Thus, irisin can inhibit high glucose‐induced EndMT and exert a dose‐dependent bidirectional effect on DCM.
- 23 October 2017
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (2) , 808-822
Open AccessIrisin inhibits high glucose‐induced endothelial‐to‐mesenchymal transition and exerts a dose‐dependent bidirectional effect on diabetic cardiomyopathy
Emerging evidence indicates that irisin provides beneficial effects in diabetes. However, whether irisin influences the development of diabetic cardiomyopathy (DCM) remains unclear. Therefore, we investigated the potential role and mechanism of action of irisin in diabetes‐induced myocardial dysfunction in mice. Type 1 diabetes was induced in mice by injecting streptozotocin, and the diabetic mice were administered recombinant r‐irisin (low or high dose: 0.5 or 1.5 μg/g body weight/day, I.P.) or PBS for 16 weeks. Irisin treatment did not alter blood glucose levels in the diabetic mice. However, the results of echocardiographical and histopathological assays indicated that low‐dose irisin treatment alleviated cardiac fibrosis and left ventricular function in the diabetic mice, whereas high‐dose irisin failed to mitigate the ventricular function impairment and increased collagen deposition. The potential mechanism underlying the effect of low‐dose irisin involved irisin‐mediated inhibition of high glucose‐induced endothelial‐to‐mesenchymal transition (EndMT); conversely, high‐dose irisin treatment enhanced high glucose‐induced MMP expression by stimulating MAPK (p38 and ERK) signalling and cardiac fibroblast proliferation and migration. Low‐dose irisin alleviated DCM development by inhibiting high glucose‐induced EndMT. By contrast, high‐dose irisin disrupted normal MMP expression and induced cardiac fibroblast proliferation and migration, which results in excess collagen deposition. Thus, irisin can inhibit high glucose‐induced EndMT and exert a dose‐dependent bidirectional effect on DCM.
- Top Cited Papers
Traditional Chinese Medicine for Cardiovascular Disease
- 1 October 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 479 (1) , 109-115
Inhibition of Pin1 alleviates myocardial fibrosis and dysfunction in STZ-induced diabetic mice
- 1 October 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 479 (1) , 109-115
Inhibition of Pin1 alleviates myocardial fibrosis and dysfunction in STZ-induced diabetic mice
- Open Access
- 11 August 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (38) , 61703-61715
Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice
Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice
- 11 August 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (38) , 61703-61715
Open AccessNeferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice
Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice
- Open Access
- 16 December 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (12) , e0145130
Tongxinluo Protects against Hypertensive Kidney Injury in Spontaneously-Hypertensive Rats by Inhibiting Oxidative Stress and Activating Forkhead Box O1 Signaling
Hypertension is an independent risk factor for the progression of chronic renal failure, and oxidative stress plays a critical role in hypertensive renal damage. Forkbox O1(FoxO1) signaling protects cells against oxidative stress and may be a useful target for treating oxidative stress-induced hypertension. Tongxinluo is a traditional Chinese medicine with cardioprotective and renoprotective functions. Therefore, this study aimed to determine the effects of Tongxinluo in hypertensive renal damage in spontaneously hypertensive rats(SHRs)and elucidate the possible involvement of oxidative stress and FoxO1 signaling in its molecular mechanisms. SHRs treated with Tongxinluo for 12 weeks showed a reduction in systolic blood pressure. In addition to increasing creatinine clearance, Tongxinluo decreased urinary albumin excretion, oxidative stress injury markers including malondialdehyde and protein carbonyls, and expression of nicotinamide adenine dinucleotide phosphate oxidase subunits and its activity in SHR kidneys. While decreasing phosphorylation of FoxO1, Tongxinluo also inhibited the phosphorylation of extracellular signal-regulated kinase1/2 and p38 and enhanced manganese superoxide dismutase and catalase activities in SHR kidneys. Furthermore, histology revealed attenuation of glomerulosclerosis and renal podocyte injury, while Tongxinluo decreased the expression of α-smooth muscle actin, extracellular matrixprotein, transforming growth factor β1 and small mothers against decapentaplegic homolog 3,and improved tubulointerstitial fibrosis in SHR kidneys. Finally, Tongxinluo inhibited inflammatory cell infiltration as well as expression of tumor necrosis factor-α and interleukin-6. In conclusion, Tongxinluo protected SHRs against hypertension-induced renal injury by exerting antioxidant, antifibrotic, and anti-inflammatory activities. Moreover, the underlying mechanisms of these effects may involve inhibition of oxidative stress and functional activation of FoxO1 signaling.
- 16 December 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (12) , e0145130
Open AccessTongxinluo Protects against Hypertensive Kidney Injury in Spontaneously-Hypertensive Rats by Inhibiting Oxidative Stress and Activating Forkhead Box O1 Signaling
Hypertension is an independent risk factor for the progression of chronic renal failure, and oxidative stress plays a critical role in hypertensive renal damage. Forkbox O1(FoxO1) signaling protects cells against oxidative stress and may be a useful target for treating oxidative stress-induced hypertension. Tongxinluo is a traditional Chinese medicine with cardioprotective and renoprotective functions. Therefore, this study aimed to determine the effects of Tongxinluo in hypertensive renal damage in spontaneously hypertensive rats(SHRs)and elucidate the possible involvement of oxidative stress and FoxO1 signaling in its molecular mechanisms. SHRs treated with Tongxinluo for 12 weeks showed a reduction in systolic blood pressure. In addition to increasing creatinine clearance, Tongxinluo decreased urinary albumin excretion, oxidative stress injury markers including malondialdehyde and protein carbonyls, and expression of nicotinamide adenine dinucleotide phosphate oxidase subunits and its activity in SHR kidneys. While decreasing phosphorylation of FoxO1, Tongxinluo also inhibited the phosphorylation of extracellular signal-regulated kinase1/2 and p38 and enhanced manganese superoxide dismutase and catalase activities in SHR kidneys. Furthermore, histology revealed attenuation of glomerulosclerosis and renal podocyte injury, while Tongxinluo decreased the expression of α-smooth muscle actin, extracellular matrixprotein, transforming growth factor β1 and small mothers against decapentaplegic homolog 3,and improved tubulointerstitial fibrosis in SHR kidneys. Finally, Tongxinluo inhibited inflammatory cell infiltration as well as expression of tumor necrosis factor-α and interleukin-6. In conclusion, Tongxinluo protected SHRs against hypertension-induced renal injury by exerting antioxidant, antifibrotic, and anti-inflammatory activities. Moreover, the underlying mechanisms of these effects may involve inhibition of oxidative stress and functional activation of FoxO1 signaling.